Suppliers and packagers for TOPAMAX

TOPAMAX

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Janssen Pharms	TOPAMAX	topiramate	CAPSULE;ORAL	020844	NDA	Janssen Pharmaceuticals, Inc.	50458-645-65	60 CAPSULE, COATED PELLETS in 1 BOTTLE (50458-645-65)	1998-11-01
Janssen Pharms	TOPAMAX	topiramate	CAPSULE;ORAL	020844	NDA	Janssen Pharmaceuticals, Inc.	50458-647-65	60 CAPSULE, COATED PELLETS in 1 BOTTLE (50458-647-65)	1998-11-01
Janssen Pharms	TOPAMAX	topiramate	TABLET;ORAL	020505	NDA	Janssen Pharmaceuticals, Inc.	50458-639-65	60 TABLET, COATED in 1 BOTTLE (50458-639-65)	1997-01-01
Janssen Pharms	TOPAMAX	topiramate	TABLET;ORAL	020505	NDA	Janssen Pharmaceuticals, Inc.	50458-640-65	60 TABLET, COATED in 1 BOTTLE (50458-640-65)	1997-01-01

Suppliers and packagers for TOPAMAX

Last updated: June 8, 2026

TOPAMAX (topiramate) Suppliers: What Companies Provide API, Finished Dosage Forms, and Contract Manufacturing for U.S. Supply

TOPAMAX is a topiramate brand with supply anchored by branded manufacturing and a large global API and generic supplier base. In the U.S., the commercial product is supplied through the branded and generic distribution chain under the FDA’s labeling and market authorization framework, while topiramate API and intermediates come from a broad set of specialty and generic-active ingredient manufacturers.

Who are the main suppliers for TOPAMAX (topiramate) in the U.S.?

The U.S. TOPAMAX supply chain has two layers: (1) the FDA-licensed branded drug product manufacturer/labeler and (2) upstream API and finished-dose CMOs supplying the generic market, where multiple ANDA filers and distributors compete.

Branded product labeler and drug product manufacturing

TOPAMAX is marketed as a branded oral dosage product (tablets and sprinkle capsules). The “labeler” and “manufacturer” roles for TOPAMAX in the U.S. appear in FDA drug product listing and Orange Book records tied to listed patents. These records identify the company responsible for the approved finished dosage form that reaches U.S. pharmacies.

Upstream topiramate API and intermediate suppliers

Topiramate API is sourced globally. The upstream supplier universe is typically concentrated in plants capable of halogenation, key intermediate hydrogenation steps, and final purification suitable for DEA-controlled logistics where applicable and for consistent impurity control that meets commercial specifications. API supply is dominated by generic-active ingredient manufacturers and multinational specialty chemicals firms, with batch-tested release documentation for NDA/ANDA and commercial distribution.

Which companies supply topiramate API used to make TOPAMAX and generics?

Topiramate API suppliers are generally the same cohort that supplies ANDA manufacturers and branded-authorized outsourcing operations. The practical supplier set can be inferred from ANDA filings, DMF holders for topiramate drug substance, and inspection-relevant manufacturing site networks.

API supplier roles that matter

• DMF holders supplying drug substance to ANDA manufacturers
• API re-packers and distributors that provide released material to multiple finished-dose firms
• Contract API manufacturers producing under commercial supply agreements

How to map “API suppliers” to business risk

For procurement and litigation readiness, the most decision-relevant supplier set is the intersection of:

• DMF site holders for topiramate drug substance
• ANDA lead firms manufacturing the tablet/capsule dosage form
• Consistency of impurity profiles tied to defect risk and potential FDA 483/Warning Letters affecting supply continuity

Do the TOPAMAX tablets and sprinkle capsules have different suppliers?

Yes, finished dosage form sourcing can differ by site and packaging line because:

• tablets require distinct compression, coating, and imprinting controls
• sprinkle capsules require micro-encapsulation or graded sprinkle blend manufacturing, plus capsule fill validation

Even when the same API supplier is used, the finished-dose CMO network for tablets can differ from the CMO network for sprinkle formulations.

What finished-dose manufacturers and CDMOs make topiramate tablets and capsules?

Finished-dose manufacturing is commonly performed by CDMOs and in-house plants tied to ANDA commercialization, with multiple sites supporting commercial throughput. The supplier list is best derived from:

• ANDA drug product manufacturing sites
• FDA facility registrations (listed under drug establishments)
• NDA/ANDA annual facility and product reporting footprints

From a supply continuity standpoint, the critical set is the number of independent manufacturing plants producing oral topiramate forms (tablets and sprinkle capsules) that can surge capacity if one site is disrupted.

How many suppliers does TOPAMAX rely on compared with generic topiramate?

Branded TOPAMAX typically relies on fewer finished-dose manufacturing lines than generic topiramate, which is produced by many ANDA holders across multiple sites. This creates:

• lower supplier diversity risk for branded products when contract manufacturing is tightly managed
• broader generic supply resilience due to plural manufacturing participation

In practice, generic topiramate supply pools are wider, and branded supply is more sensitive to specific site disruptions or packaging line constraints.

Which suppliers have FDA inspection exposure risks for topiramate?

The inspection exposure set for topiramate is determined by:

• recent FDA inspections of oral solid dose plants
• past compliance actions affecting impurity control, cross-contamination prevention, and data integrity
• Warning Letters or Form 483 observations tied to quality system failures

For business planning, the risk is not the number of suppliers, but the presence of single points of failure among active manufacturing sites.

What is the Orange Book status of TOPAMAX relevant to supplier onboarding?

Orange Book listings for TOPAMAX list drug product and patent-linked exclusivity, which affects market entry timing for competitors. That status does not directly name suppliers, but it controls:

• which ANDA applicants can launch
• whether branded supply agreements and authorized generics exist
• whether litigation settlement terms constrain manufacturing or marketing

Patent and exclusivity timing influences which firms commit to manufacturing capacity for the oral solid dose portfolio.

What generic entry risks affect who supplies topiramate tablets and capsules?

Generic entry risk is driven by:

• Paragraph IV challenges to TOPAMAX-related patents
• settlement agreements that may delay or restrict entry
• patent thickets around formulations, dosage forms, and method-of-use

Supplier commitments to commercial production often track litigation outcomes because they determine expected launch dates and margin feasibility.

Does TOPAMAX have authorized generics or licensing that expand the supplier base?

Authorized generic or license-style supply arrangements can add suppliers to the market, but the presence of such structures is a product-specific, agreement-specific matter reflected in approvals, marketing authorization, and Orange Book-era launch history.

Where authorized generics exist, they usually expand distribution without changing API supplier identity, but they do increase finished-dose manufacturing participation.

Which firms are the major ANDA suppliers for topiramate tablets and sprinkle products?

Major ANDA suppliers for topiramate typically include:

• large generic manufacturers with high-volume oral solid dose portfolios
• specialty generic firms focused on CNS and chronic neurology brands
• regional generic manufacturers that compete on price in specific channels

For procurement and litigation mapping, the target list is the ANDA holder group that is actively manufacturing and selling topiramate equivalents in the relevant dosage strengths.

How does TOPAMAX compare with generic topiramate supplier concentration?

Branded supply tends to be concentrated in fewer validated production sites, while generic competition adds:

• multiple dosage-strength-specific manufacturers
• multiple packaging and distribution partners
• alternative formulations that still meet bioequivalence requirements

The practical difference for buyers is reliability under supply disruption and ability to qualify alternate suppliers quickly.

Key Takeaways

• TOPAMAX supply in the U.S. is anchored by branded finished-dose manufacturing and labeling under FDA-reviewed product listing frameworks.
• The upstream topiramate API supplier base is broad globally and typically overlaps with ANDA drug substance and drug product networks.
• Tablet and sprinkle capsule supply can involve different finished-dose manufacturing lines and CDMO participation.
• Generic supply is less concentrated than branded supply due to multiple ANDA holders, which improves continuity but increases QA and compliance variability risk across sites.
• Patent and Orange Book exclusivity dynamics govern competitor launch timing and therefore influence which suppliers invest in manufacturing capacity.

FAQs

1. How can I identify the FDA drug product manufacturer for TOPAMAX tablets and sprinkle capsules?
   Use FDA drug product listing entries tied to the TOPAMAX NDA and cross-check with Orange Book listings for listed product and patent coverage.

2. What is the difference between topiramate API suppliers and topiramate finished-dose manufacturers?
   API suppliers produce the drug substance, while finished-dose manufacturers produce tablets/capsules, handle blending, compression or capsule filling, coating, packaging, and release testing.

3. Which factors determine whether a CDMO is qualified to supply topiramate oral solids?
   Solid oral dose capability, impurity and residual solvent controls, validated mixing and blending, cross-contamination controls, and GMP quality systems for CNS-active ingredients.

4. How do Paragraph IV challenges influence topiramate supplier availability?
   They can delay generic market entry, reducing near-term demand for certain manufacturing capacity and shifting investment toward later launch windows or alternative sites.

5. Do topiramate formulation changes create separate supplier qualification hurdles?
   Yes. Differences like capsule sprinkle technology versus tablet coating and imprinting can require distinct process validation and packaging qualification, even when the API is the same.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drugs@FDA. U.S. Food and Drug Administration.
3. FDA. National Drug Code (NDC) Directory. U.S. Food and Drug Administration.
4. FDA. Drug Establishment Registration and Listing (DERL). U.S. Food and Drug Administration.